August 15, 2007

US pharma lobby rues court ruling

The Pharmaceutical Research and Manufacturers of America, a representative body of US drug firms, has lambasted the Indian court's decision on the Glivec case, saying it will weaken incentives for new innovations. The association CEO Billy Tauzin said, "We are disappointed the Indian court dismissed the challenge to Section 3 (d) of India's 2005 Patent Law. We are concerned that the result is likely to be reduced patient access to better medicines discovered through incremental innovation."

Tauzin added, "Breakthrough innovations are important but rare in medical research. Most medical advances like in other technological fields happen by incremental innovation; that is, innovation that builds on previous inventions."

The Pharmaceutical Research and Manufacturers of America (PhRMA) members alone invested an estimated $43 billion in 2006 to discover and develop new medicines. Industry-wide research and investment reached a record $55.2 billion in 2006.

"In this industry, incremental innovation means continuous improvement of medicines that have been key to delivering therapeutic advances to patients worldwide. Incremental innovation requires large-scale research and development before the new product can be offered to patients," the CEO said.

No comments:

ShareThis

LinkWithin

Related Posts with Thumbnails

Categories